Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Markos D Patsouras"'
Publikováno v:
Journal of autoimmunity. 115
Objective Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized by recurrent thrombosis and/or pregnancy morbidity, in the presence of antibodies to β2 glycoprotein-I (β2GPI), prothrombin or Lupus anticoagulant (LA). Anti-β2GP
Autor:
Paraskevi Kogionou, Karagianni Panagiota, Markos D Patsouras, Panayiotis G. Vlachoyiannopoulos
Publikováno v:
Poster Presentations.
Autor:
Theodoros Angelopoulos, Georgia Liantinioti, Panagiota Katsouli, Vlachoyiannopoulos Panayiotis, Mary Pappa, Sotiris Roussos, Olga Katsouli, Markos D Patsouras
Publikováno v:
Abstracts Accepted for Publication.
Background: Rheumatoid arthritis (RA) is treated successfully with biologic disease-modifying anti-rheumatic drugs (bDMARDs). However, a significant withdrawal rate, due to non-responsiveness or toxicity, remains a major barrier for their long-term u
Publikováno v:
Journal of autoimmunity. 102
Background Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by recurrent thromboembolism and/or pregnancy morbidity in the presence of Antiphospholipid antibodies, mainly anti-β2 glycoprotein I (anti-β2GPI). The autoanti
Autor:
Panayiotis G. Vlachoyiannopoulos, Marina P. Sikara, Eleftheria P. Grika, Markos D Patsouras, Athanasios G. Tzioufas, Haralampos M. Moutsopoulos
Publikováno v:
Journal of Autoimmunity. 65:30-37
Platelet factor 4 tetramers (CXCL4 chemokine) form complexes with β2glycoprotein I (β2GPI), recognized by anti-β2GPI antibodies leading to platelet activation in antiphospholipid syndrome (APS), either primary (PAPS) or secondary (SAPS). Increased
Autor:
Clio P. Mavragani, Panagiotis F. Christopoulos, Nikolaos I. Vlachogiannis, Markos D Patsouras, P.P. Sfikakis, V.-K. Bournia, P. G. Vlachoyiannopoulos, Andrianos Nezos
Publikováno v:
Poster Presentations.
Background Type I Interferon (IFN) pathway is activated in Systemic Sclerosis (SSc) and represents a therapeutic target currently being tested in clinical trials, while higher IFNα levels have been also associated with pulmonary fibrosis in these pa
Publikováno v:
Autoimmune inflammation.
Background Antiphospholipid syndrome (APS) is an acquired thombophillia characterised by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a r glycoprotein secreted by platelets upon activation with proinflammatory, antiang
Autor:
Eleni Papakonstantinou, Panayiotis G. Vlachoyiannopoulos, Elias Eliopoulos, Markos D Patsouras
Publikováno v:
New players and novel targets in inflammation.
Background Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterised by recurrent thromboembolism and or pregnancy morbidity in the presence of antiphospholid antibodies (aPL). Major auto antigen is B2 Glycoprotein I (Β2GPI). APL
Autor:
P. G. Vlachoyiannopoulos, Aglaia G Vakrakou, Athanasios G. Tzioufas, Menelaos N. Manoussakis, Markos D Patsouras
Publikováno v:
Autoimmune inflammation.
Sjogren’s syndrome (SS) patients manifest inflammation in salivary glands (SG) and evidence of intrinsic activation in the salivary gland epithelial cells (SGEC). Recent evidence from this laboratory has indicated that the aberrant exposure of SGEC
Publikováno v:
Journal of Autoimmunity. 104:102347
Thrombosis in the context of Cardiovascular disease (CVD) affects mainly the blood vessels supplying the heart, brain and peripheries and it is the leading cause of death worldwide. The pathophysiological thrombotic mechanisms are largely unknown. He